

Mrkt BUZZ DanCann Pharma: Strengthens future pipeline by at least SEK 37 million

Carlsquare Equity Research comments on DanCann's letter of intent with Aureum Pharma.

Read the comment here.

About Carlsquare

Carlsquare is a Pan-European research firm and financial advisor, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 80+ employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team have an extensive experience about the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Berlin, Copenhagen, Hamburg, London, Munich and Stockholm. Read more

Contact
MARKUS AUGUSTSSON
Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20

Contacts

MARKUS AUGUSTSSON

Head of Equity Research markus.augustsson@carlsquare.com +46 (0)76 235 03 20

NIKLAS ELMHAMMER

Senior Equity Analyst niklas.elmhammer@carlsquare.com +46 (0)70 898 39 59

Attachments

Mrkt BUZZ DanCann Pharma: Strengthens future pipeline by at least SEK 37 million